A Multicenter, Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6885247 Following 12 Weeks of Treatment in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH).
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2017
Price : $35 *
At a glance
- Drugs RG 7800 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Acronyms MOONFISH
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 23 Dec 2016 This trial has been completed in Spain (end date: 12 Dec 2016).
- 20 Dec 2016 Status changed from suspended to discontinued due to unexpected toxicology, Dosing was suspended, the study was put on hold and eventually terminated..